CareDx Expands Precision Oncology Portfolio with Naveris Acquisition

(Brisbane, CA, USA), a precision medicine company advancing clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, has entered a definitive agreement to acquire Naveris (Waltham, MA, USA). Naveris is a commercial-stage precision oncology diagnostics company with a Medicare-reimbursed, blood-based monitoring solution for viral-mediated cancers.

Naveris’ platform centers on Tumor Tissue Modified Viral (TTMV) DNA. Its proprietary NavDx test detects TTMV human papillomavirus (HPV) DNA and is clinically validated as a circulating tumor DNA (ctDNA) assay for post-treatment surveillance and molecular residual disease (MRD) assessment. The company reports that more than 130,000 commercial tests have been performed and its solution is described as a leading option for MRD surveillance in head and neck and anal cancers.

The TTMV approach measures fragments of viral DNA shed from tumor tissue into the bloodstream, providing a tumor‑naïve strategy designed to support patients from initial diagnosis through post‑therapy monitoring. As a liquid biopsy methodology, the platform is intended for repeat testing in specialties where a high burden of disease necessitates ongoing surveillance. Medicare coverage for the test was established in 2023.

Under the agreement, consideration includes $160 million in up‑front cash and up to $100 million tied to revenue milestones. Naveris reported unaudited 2025 revenue of $34 million and approximately $12 million for the first quarter of 2026, with gross margins of 65% and a small net operating loss. The parties anticipate closing in the third quarter of 2026, subject to customary closing conditions. 

“Naveris has developed and commercialized a liquid biopsy monitoring platform proven to detect cancer earlier and with greater accuracy than conventional approaches,” said James B. McNally, Chief Executive Officer of Naveris. “We are thrilled to be combining forces with CareDx to fulfill our mission of improving patient outcomes by delivering disruptive technology that transforms cancer care and expanding patient access to precision medicine.”

“Today’s announcement accelerates our growth strategy in Precision Medicine Testing Services and Patient & Digital Solutions. We are focused on being a leader in concentrated specialty markets where a high burden of disease drives repeat testing. Naveris fits that profile with a differentiated technology that is early in its adoption,” said John Hanna, President & CEO of CareDx. 

“Naveris is poised for strong growth, leveraging our core capabilities—building belief in molecular testing, simplifying clinical workflow, and generating evidence for coverage and reimbursement,” said Hanna.

Related Links
CareDx 
Naveris